Genmab A/s -sp Adr (GMAB) — 13F Holders Deep Dive (Q2 2026)

GMAB ranks #2170 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

GMAB is a top-conviction position for Superstring Capital Management LP — at 7.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in GMAB belongs to Paradigm Biocapital Advisors LP, but the position matters far more to Superstring Capital Management LP, who has 7.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Ken Griffin has added to its GMAB position for two straight quarters, increasing it by $76.0M to reach $77.8M today.

Orbis Allan Gray Ltd has trimmed its GMAB position for two straight quarters, cutting it by $131.8M while still holding $312.3M.

GMAB is up 2.8% today, and institutions have been net buyers of $700.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

GMAB posted net income of $5.0B over the trailing twelve months.

• Profitable — net income of $5.0B over the trailing twelve months
• Revenue declined 10.4% year over year
• Net income improved year over year, from $4.9B to $5.0B
• Generated $1.2B in positive operating cash flow
• Current ratio of 2.02x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.20x equity — within a conventional range